Revance Therapeutics, Inc the biopharmaceutical company has began Phse Ib clinical trial of topical application botulinum toxin type A gel. The gel helps in the treatment of facial lines and wrinkles. Clinical trials are designed to demonstrate the effects of topically applied botulinum toxin in reducing wrinkles and preserving facial expressions. The study evaluates composite measurements and photos of improvement in wrinkles and fine lines before and after the application. If successful, the macromolecule delivery and botulinum toxin, would be a major advancement in facial aesthetics.

To know more information contact Revance Therapeutics, Inc. Pam Wadler / Nancy Trent, 212-966-0024